Hyperion DeFi, Inc. (HYPD)
NASDAQ: HYPD · Real-Time Price · USD
6.80
-1.37 (-16.77%)
Jul 25, 2025, 12:47 PM - Market open

Company Description

Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States.

The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals.

Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025.

Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York.

Hyperion DeFi, Inc.
Hyperion DeFi logo
CountryUnited States
Founded2014
IPO DateJan 25, 2018
IndustryBiotechnology
SectorHealthcare
Employees14
CEOMichael Rowe

Contact Details

Address:
295 Madison Avenue, Suite 2400
New York, New York 10017
United States
Phone917 289 1117
Websiteeyenovia.com

Stock Details

Ticker SymbolHYPD
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001682639
Employer ID47-1178401
SIC Code2834

Key Executives

NamePosition
Michael RoweChief Executive Officer
Michael RoweChief Financial Officer
Bren KernChief Operating Officer

Latest SEC Filings

DateTypeTitle
Jul 24, 2025ARSFiling
Jul 24, 2025DEF 14AOther definitive proxy statements
Jul 22, 2025DNotice of Exempt Offering of Securities
Jul 22, 2025144Filing
Jul 18, 2025S-3Registration statement under Securities Act of 1933
Jul 16, 2025SCHEDULE 13DFiling
Jul 11, 2025PRE 14AOther preliminary proxy statements
Jul 7, 2025424B5Filing
Jul 2, 2025SCHEDULE 13D/AFiling
Jul 2, 20258-KCurrent Report